Quoin Pharmaceuticals (QNRX) Director Dennis Langer Acquires 34,534 ADSs

What Happened
Dennis Langer, a director of Quoin Pharmaceuticals, acquired 34,534 American Depositary Shares (ADSs) on August 27, 2026 at an implied price of $5.15 per ADS, a total reported value of $177,850. The ADSs were issued in exchange for accrued interest/outstanding debt tied to a note previously held by Langer (non-cash transaction).

Key Details

• Transaction date and price: 2026-08-27; 34,534 ADSs at $5.15 per ADS (total reported value $177,850). Footnote states $177,849 of accrued interest was exchanged.
• Shares owned after transaction: Not disclosed in the Form 4 filing.
• Transaction type/code: Acquisition (A) — debt-for-equity exchange, not an open-market buy.
• ADS conversion: Each ADS represents 35 ordinary shares, so 34,534 ADSs equal 1,208,690 ordinary shares (see footnote).
• Approvals: The exchange agreement and issuance were approved by Quoin’s audit committee and board of directors (per filing).
• Timeliness: Filed 2026-08-28 for a transaction on 2026-08-27 (appears timely).

Context
This was a non-cash debt-for-equity exchange: Langer converted accrued interest/outstanding debt into ADSs rather than buying shares with cash. Such transactions increase insider equity ownership but differ from open-market purchases because they settle creditor claims rather than reflect new cash investment. The audit committee and board approval is a governance note, not an indication of intent or future company performance.